These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 30291682)
1. Clinical evaluation of the lightening effect of cytidine on hyperpigmented skin. Baswan SM; Leverett J; Pawelek J J Cosmet Dermatol; 2019 Feb; 18(1):278-285. PubMed ID: 30291682 [TBL] [Abstract][Full Text] [Related]
2. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging. Serra M; Bohnert K; Narda M; Granger C; Sadick N J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263 [TBL] [Abstract][Full Text] [Related]
3. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Hakozaki T; Minwalla L; Zhuang J; Chhoa M; Matsubara A; Miyamoto K; Greatens A; Hillebrand GG; Bissett DL; Boissy RE Br J Dermatol; 2002 Jul; 147(1):20-31. PubMed ID: 12100180 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a depigmenting gel serum comprising tranexamic acid, niacinamide, 4-butylresorcinol, phytic acid, and a mixture of hydroxy acids that targets the biological processes regulating skin melanogenesis. Furmanczyk M; Brown A; Bustos J; de Henestrosa ARF; Trullas C; Granger C; Jourdan E J Cosmet Dermatol; 2024 Jun; 23(6):2058-2065. PubMed ID: 38549196 [TBL] [Abstract][Full Text] [Related]
8. Reduction in the appearance of facial hyperpigmentation by topical N-undecyl-10-enoyl-L-phenylalanine and its combination with niacinamide. Bissett DL; Robinson LR; Raleigh PS; Miyamoto K; Hakozaki T; Li J; Kelm GR J Cosmet Dermatol; 2009 Dec; 8(4):260-6. PubMed ID: 19958429 [TBL] [Abstract][Full Text] [Related]
9. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone. Draelos ZD J Am Acad Dermatol; 2015 Jan; 72(1):105-7. PubMed ID: 25440437 [TBL] [Abstract][Full Text] [Related]
10. Antimelanogenic activity of a novel adamantyl benzylbenzamide derivative, AP736: a randomized, double-blind, vehicle-controlled comparative clinical trial performed in patients with hyperpigmentation during the summer. Jeong YS; Kim JH; Choi J; Baek HS; Joo YH; Lee CS; Shin HJ; Park YH; Kim BJ; Shin SS Int J Dermatol; 2016 Jun; 55(6):e321-6. PubMed ID: 26712041 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of topical depigmenting agent in healthy human fair skin female volunteers: A single-arm study. Shah S; Chew SK J Cosmet Dermatol; 2018 Oct; 17(5):830-839. PubMed ID: 29193788 [TBL] [Abstract][Full Text] [Related]
12. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Greatens A; Hakozaki T; Koshoffer A; Epstein H; Schwemberger S; Babcock G; Bissett D; Takiwaki H; Arase S; Wickett RR; Boissy RE Exp Dermatol; 2005 Jul; 14(7):498-508. PubMed ID: 15946237 [TBL] [Abstract][Full Text] [Related]
13. Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial. Lee DH; Oh IY; Koo KT; Suk JM; Jung SW; Park JO; Kim BJ; Choi YM Skin Res Technol; 2014 May; 20(2):208-12. PubMed ID: 24033822 [TBL] [Abstract][Full Text] [Related]
14. The combination of sucrose dilaurate and sucrose laurate suppresses HMGB1: an enhancer of melanocyte dendricity and melanosome transfer to keratinocytes. Wang J; Jarrold B; Zhao W; Deng G; Moulton L; Laughlin T; Hakozaki T J Eur Acad Dermatol Venereol; 2022 Feb; 36 Suppl 3():3-11. PubMed ID: 35014730 [TBL] [Abstract][Full Text] [Related]
15. Approach to Skin Lightening in Patients With Melasma. Cohen PR J Drugs Dermatol; 2018 Sep; 17(9):1018. PubMed ID: 30235392 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of novel topical pigment-correcting regimen with biweekly diamond tip microdermabrasion procedures on facial hyperpigmentation. Goberdhan L; Schneider K; Makino ET; Bautista A; Mehta RC J Cosmet Dermatol; 2024 May; 23(5):1726-1733. PubMed ID: 38288515 [TBL] [Abstract][Full Text] [Related]
17. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation. Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061 [TBL] [Abstract][Full Text] [Related]
18. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. Kolbe L; Mann T; Gerwat W; Batzer J; Ahlheit S; Scherner C; Wenck H; Stäb F J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():19-23. PubMed ID: 23205541 [TBL] [Abstract][Full Text] [Related]